Privigen Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of plasma donation networks, rising diagnosis of primary immunodeficiency disorders, availability of plasma-derived therapies, improved clinical guidelines for ivig use, growth of hospital-based infusion services.

The growth in the forecast period can be attributed to increasing demand for long-term immunotherapy treatments, expansion of homecare infusion services, rising investment in plasma supply security, growing prevalence of autoimmune disorders, improved manufacturing efficiency for ivig products. Major trends in the forecast period include increasing demand for immunoglobulin therapies, expansion of plasma collection infrastructure, rising use of home-based ivig administration, improved plasma fractionation technologies, growing focus on chronic immune disorders.

The rising prevalence of immunodeficiency disorders is expected to drive the growth of the Privigen market. Immunodeficiency disorders impair the immune system’s ability to defend the body against infections and diseases. The increasing prevalence is fueled by factors such as greater awareness, improved diagnostic capabilities, longer survival of individuals with primary immunodeficiencies, increased use of immunosuppressive therapies, and higher rates of chronic diseases. Privigen, an intravenous immunoglobulin (IVIG), helps treat these disorders by boosting antibody levels, enabling patients to fight infections and maintain immune function. For example, in May 2023, according to the University of Oxford, the 19 most common autoimmune diseases affected 3-9% of the UK population in 2022, rising to 10% in 2023. Therefore, the growing prevalence of immunodeficiency disorders is driving the Privigen market.

Rising healthcare expenditure is also expected to propel the Privigen market. Healthcare expenditure includes spending on medical services, infrastructure, pharmaceuticals, and healthcare activities. Increasing expenditure is driven by higher operational costs, rising chronic and lifestyle-related diseases, greater prevalence of genetic disorders, advances in medical technology, and improved access to healthcare. Higher spending enhances access to therapies such as Privigen, improving treatment availability, patient outcomes, and overall healthcare infrastructure. For instance, in May 2024, according to the UK Office for National Statistics, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% in 2022, while total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, increasing healthcare expenditure is driving the Privigen market.

The rise in favorable government initiatives is also supporting the growth of the Privigen market. Government initiatives include programs and policies aimed at improving public health, enhancing access to medical services, and promoting overall population well-being. These initiatives are increasing due to higher demand for affordable medical services, the need to address aging populations and chronic diseases, and advances in medical technology. Supportive government programs improve access to therapies such as Privigen by ensuring affordable and timely care through funding and healthcare schemes. For example, in February 2023, according to the National Institute for Health and Care Research, UK-based funding for the NIHR BioResource program, which uses genetic information to develop new tests and treatments for rare diseases including immunodeficiencies, increased from $50.89 million in 2022 to $1.0 billion in 2023. Therefore, favorable government initiatives are driving the growth of the Privigen market.

Major companies operating in the privigen market are CSL Behring AG.

North America was the largest region in the privigen market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the privigen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the privigen market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the privigen market by increasing costs of imported plasma processing equipment, fractionation systems, sterile packaging materials, and cold-chain transportation infrastructure. North America and Europe are most affected due to reliance on global plasma supply chains and cross-border manufacturing processes. These tariffs contribute to higher treatment costs and supply constraints for immunoglobulin therapies. However, they are also encouraging domestic plasma collection expansion, localized manufacturing investments, and long-term improvements in regional plasma self-sufficiency.

The privigen market research report is one of a series of new reports that provides privigen market statistics, including privigen industry global market size, regional shares, competitors with a privigen market share, detailed privigen market segments, market trends and opportunities, and any further data you may need to thrive in the privigen industry. This privigen market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Privigen is an intravenous immunoglobulin (IVIg) therapy derived from human plasma. It is used to manage conditions associated with weakened immune systems, such as primary immunodeficiency (PI), chronic inflammatory demyelinating polyneuropathy (CIDP), and idiopathic thrombocytopenic purpura (ITP). Privigen works by providing antibodies that help the body fight infections and regulate immune responses.

The main formulations of Privigen are liquid (10% solution) and lyophilized. The liquid 10% solution is a sterile IVIg preparation used to treat immunodeficiency and autoimmune disorders by supplying essential antibodies. The indications include primary immunodeficiency (PI), CIDP, ITP, Guillain-Barré syndrome, and others. Privigen is used by hospitals, clinics, and home care settings.

The privigen market consists of sales of privigen liquid for primary immunodeficiency, liquid for chronic immune thrombocytopenic purpura, and liquid for chronic inflammatory demyelinating polyneuropathy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.